Announcements Trials
Browse Landscape

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 12Observational 1

Sponsor

Cancer Type

CNS 1

Conditions

Neuroblastoma 1

Interventions

Sunitinib 16exemestane 11Afatinib 11palbociclib 10Rituximab 10Bevacizumab 10Erlotinib Hydrochloride 9Leuprolide 8Radiotherapy 7Drug Therapy 7Axitinib 7avelumab 6Letrozole 6Capecitabine 6Blood Specimen Collection 6enzalutamide 5Trastuzumab 5Surveys and Questionnaires 5Standard of Care 5Docetaxel 5Aromatase Inhibitors 5lorlatinib 4Specimen Handling 4Radiation 4Mammography 4Crizotinib 4Anastrozole 4Abiraterone Acetate 4temsirolimus 3talazoparib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Observational × Has results × dinutuximab × Clear all
NCT02693171 2019-08-05

Post-Marketing Assessment of Immunogenicity and Safety of Unituxin® in High-Risk Neuroblastoma Patients

United Therapeutics

Terminated
13 enrolled 9 charts
CNS

Neuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡